Deep-tech diligence often starts with the question that feels most objective: does the science work? It is an important question, but it is rarely the whole problem. Many serious deep-tech companies are not weak because the science is fake. They are weak because the translation from working science to fundable company is under-evidenced.
A lab result can be true while the commercial case is still fragile. A patent can issue while the moat is still narrow. A pilot can impress technical users while the buyer, channel partner, reimbursement gate, or procurement process remains unresolved.
Feasibility is a threshold question. It is not the same as company readiness.
The VentureIP read separates those two ideas. We want the fund to know whether the invention is real, where the technical case is strong, and which missing proofs would have to appear before the company deserves higher confidence.
The familiar profile
The pattern is common: strong problem, credible technical work, and a founder who can explain the invention clearly. Those signals matter. They are usually why the deal reaches the partner meeting.
The pressure points show up elsewhere.
- Customer pull is described more strongly than it is proven.
- Ecosystem support is assumed because one stakeholder is excited.
- Buildability is supported by lab evidence, not production evidence.
- The business model ignores the cost and time required to make the technology reliable at scale.
None of those findings automatically kills a deal. They change what the deal is. Instead of "science works, proceed," the investment committee is looking at a technical asset with a company-readiness gap that must close inside a specific financing window.
Why feasibility can mislead
Technical feasibility produces evidence investors can touch: assays, prototypes, simulations, demos, patents, test reports, and published work. Those artifacts create confidence quickly.
Company readiness depends on the system around the invention. That system includes budget owners, manufacturing partners, regulators, standards bodies, integration partners, service obligations, and follow-on capital requirements.
The danger is letting concrete technical evidence stand in for missing system evidence. A working prototype becomes a proxy for manufacturability. A positive pilot becomes a proxy for willingness to pay. A patent family becomes a proxy for defensibility. Each proxy may be directionally useful, but none is enough on its own.
The evidence that moves the score
A useful assessment does not punish an early company for being early. It names the proof that would move the score.
For customer pull, that may mean evidence from the budget owner, not only the technical user. For ecosystem fit, it may mean a map of every party that must approve, reimburse, adopt, distribute, install, maintain, or trust the product. For buildability, it may mean a manufacturing yield plan, quality roadmap, or stress test outside lab conditions.
The next proof has to be specific enough for the fund to underwrite. "More customer validation" is too vague. "Convert two pilots into paid commitments from the economic buyer before the next tranche" is useful.
The investment committee implication
The science can work and the company can still be a poor fit for the fund's risk model. The reverse can also be true: the company may have an incomplete proof package, but the missing pieces are knowable, sequenced, and fundable.
A technically strong deal with a weak company-readiness score needs a different memo than a technically weak deal. The first memo should not argue about whether the invention is real. It should argue about whether the remaining translation risk is acceptable, who owns it, what it will cost to retire, and how quickly the evidence can be created.
How VentureIP uses the pattern
In the Cipher scorecard, feasibility sits beside the other commercialization tests rather than above them. A high technical score does not erase pressure in customer pull, ecosystem fit, buildability, or business model durability.
The output should help an investment committee say one of three things:
- The science is not yet proven enough for this round.
- The science is credible, but the company-readiness gap is too wide.
- The science is credible, the gap is named, and the next proof is narrow enough to underwrite.
That third answer is where deep-tech diligence becomes useful. It turns uncertainty into a work plan the fund can evaluate.